Skip to content

Author

A. I. Rojo

1 paper indexed here

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Review Sep 2026

Neuroinflammation and vascular pathology in Alzheimer's Disease: The NRF2/HO-1 axis as a modulator of microglial phenotypes.

Alzheimer's disease (AD) frequently co-occurs with vascular pathology, and this overlap is increasingly recognized as a major driver of cognitive decline in mixed dementia and vascular cognitive impairment and dementia (VCID). Disruption of the neurovascular unit (NVU) creates a perivascular microenvironment rich in inflammatory and oxidative cues that can instruct microglial state transitions. In this review, we argue that perivascular microglia represent a key "decision hub" at the neurovascular interface, where shifts from homeostatic surveillance toward disease-associated microglia (DAM) programs influence both amyloid handling and the amplification of neuroinflammation. We propose that the NRF2/HO-1 axis functions as a context-sensitive phenotype-control module in these niches: NRF2 integrates oxidative/electrophilic stress through KEAP1 and signaling-dependent regulation through the GSK-3/β-TrCP pathway, thereby shaping transcriptional programs that govern inflammatory tone, redox balance, iron handling, and phagocytic competence. Within this network, HO-1 emerges as a key effector because its metabolites, carbon monoxide, bile pigments, and iron-ferritin responses, can modulate innate immune signaling and, potentially, paracrine communication across NVU cell types. We synthesize evidence linking NVU dysfunction to perivascular microglial activation and discuss how NRF2/HO-1 engagement may remain compensatory in early or acute settings yet become maladaptive under chronic stress or prolonged HO-1 activity. Finally, we outline therapeutic implications of targeting NRF2/HO-1 to reprogram perivascular microglia toward protective DAM functions, emphasizing target engagement, timing, dose, and cell-type specificity as critical determinants of translational success.

M. Olazabal-Chias, M. Kratochvil, A. I. Rojo · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.